Hypercholesterolemia-induced LXR signaling in smooth muscle cells contributes to vascular lesion remodeling and visceral function

H Hanming Zhang D Diego Sáenz de Urturi (Vascular Biology and Therapeutics Program, Yale University School of Medicine) P Pablo Fernández-Tussy (Vascular Biology and Therapeutics Program, Yale University School of Medicine) Y Yan Huang D Daniel G. Jovin (Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine) X Xinbo Zhang (Vascular Biology and Therapeutics Program, Yale University School of Medicine) S Shushu Huang (Deparment of Genetics, Yale University School of Medicine) M Monkol Lek (Department of Genetics, Yale School of Medicine) J Jonatas da Silva Catarino (Department of Comparative Medicine, Yale University School of Medicine) M Magdalena Sternak (Vascular Biology and Therapeutics Program, Yale University School of Medicine) K Kathryn M. Citrin (Vascular Biology and Therapeutics Program, Yale University School of Medicine) F Fillip K. Swirski (Caridovascular Research Institute, Icahn School of Medicine at Mount Sinai) J Jan-Ake Gustafsson (Center for Nuclear Receptors and Cell Signaling, Department of Biology and Biochemistry, University of Houston) D Daniel M. Greif (Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine) E Enric Esplugues (Vascular Biology and Therapeutics Program, Yale University School of Medicine) L Lauren A. Biwer (Vascular Biology and Therapeutics Program, Yale University School of Medicine) Y Yajaira Suárez C Carlos Fernández-Hernando

Abstract

Vascular smooth muscle cells (VSMC) are the most abundant cell type in the artery’s media layer and regulate vascular tone and lesion remodeling during atherogenesis. Like monocyte-derived macrophages, VSMCs accumulate excess lipids and contribute to the total intimal foam cell population in human coronary plaques and mouse aortic atheroma. While there are extensive studies characterizing the contribution of lipid metabolism in macrophage immunometabolic responses in atherosclerotic plaques, the role of VSMC lipid metabolism in regulating vascular function and lesion remodeling in vivo remains poorly understood. Here, we report that the liver X receptor (LXR) signaling pathway in VSMC is continuously activated during atherogenesis. Notably, we found that LXR deficiency in SMCs under hypercholesterolemic conditions influenced lesion remodeling by altering the fate of dedifferentiated SMCs and promoting the accumulation of VSMC-derived transitional cells. This phenotypic switching was accompanied by reduced indices of plaque stability, characterized by a larger necrotic core area and reduced fibrous cap thickness. Moreover, SMC-specific LXR deficiency impaired vascular function and caused visceral myopathy characterized by maladaptive bladder remodeling and gut lipid malabsorption. Mechanistically, we found that the expression of several genes involved in cholesterol efflux and FA synthesis including Abca1 , Srebf1 , Scd1 , Scd2 , Acsl3, and Mid1ip1 was downregulated in mice lacking LXRαβ in SMCs, likely contributing to the phenotypic switching of VSMC in the atherosclerotic lesions.

Article Details

Volume / Issue Vol. 122, Issue 10
Published March 11, 2025
ISSN 0027-8424
Publisher National Academy of Sciences

Authors (18)

H

Hanming Zhang

D

Diego Sáenz de Urturi

Vascular Biology and Therapeutics Program, Yale University School of Medicine

P

Pablo Fernández-Tussy

Vascular Biology and Therapeutics Program, Yale University School of Medicine

Y

Yan Huang

D

Daniel G. Jovin

Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine

X

Xinbo Zhang

Vascular Biology and Therapeutics Program, Yale University School of Medicine

S

Shushu Huang

Deparment of Genetics, Yale University School of Medicine

M

Monkol Lek

Department of Genetics, Yale School of Medicine

J

Jonatas da Silva Catarino

Department of Comparative Medicine, Yale University School of Medicine

M

Magdalena Sternak

Vascular Biology and Therapeutics Program, Yale University School of Medicine

K

Kathryn M. Citrin

Vascular Biology and Therapeutics Program, Yale University School of Medicine

F

Fillip K. Swirski

Caridovascular Research Institute, Icahn School of Medicine at Mount Sinai

J

Jan-Ake Gustafsson

Center for Nuclear Receptors and Cell Signaling, Department of Biology and Biochemistry, University of Houston

D

Daniel M. Greif

Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine

E

Enric Esplugues

Vascular Biology and Therapeutics Program, Yale University School of Medicine

L

Lauren A. Biwer

Vascular Biology and Therapeutics Program, Yale University School of Medicine

Y

Yajaira Suárez

C

Carlos Fernández-Hernando